Javascript must be enabled to continue!
Comparison and evaluation of efficacy of tacrolimus 0.1% and triamcinolone acetonide 0.1% in the management of symptomatic oral lichen planus.
View through CrossRef
Objective: To evaluate and compare the effectiveness of tacrolimus 0.1% and triamcinolone acetonide 0.1% used topically to treat symptomatic OLP. Study Design: Cross sectional study. Setting: Oral Medicine Isra Dental College Hyderabad. Period: 1st February 2022 to 31st January 2023. Material & Methods: Total 60 clinically diagnosed patients of symptomatic oral lichen planus were included in study, 60 patients were equally divided into two groups as Group A and group B. Thirty patients of OLP group A were treated with Tracolimus 0.1% four times per day for four weeks and patients of group B were treated with Triamcinolone Acetonide 0.1% ointment. Results: Total 60 symptomatic OLP patients were categorized into to equal groups A and B group. OLP was commonly found in female as compare to male, VAS score and clinical score was calculated before and after the treatment, the mean VAS score of group A was 9.2 (SD±2.07) and group B was 8.9 (SD±2.07) before the treatment. While VAS score of group A 1.9 (SD±1.18) which was treated with tacrolimus (0.1%) and group B score was 2.3 (SD±1.49) which was treated with triamcinolone (0.1%) after the treatment. The mean clinical score of group A was 4.2 (SD±1.14) and 4.6 (SD±1.28) in group B before treatment. Mean clinical score was 1.8 (SD±0.87) in group A and 2.4 (SD±0.9) in group-B after treatment. Conclusion: Study reported Tacrolimus 0.1% is more effective then triamcinolone 0.1% for the treatment of symptomatic OLP however there was no reoccurrence found.
Title: Comparison and evaluation of efficacy of tacrolimus 0.1% and triamcinolone acetonide 0.1% in the management of symptomatic oral lichen planus.
Description:
Objective: To evaluate and compare the effectiveness of tacrolimus 0.
1% and triamcinolone acetonide 0.
1% used topically to treat symptomatic OLP.
Study Design: Cross sectional study.
Setting: Oral Medicine Isra Dental College Hyderabad.
Period: 1st February 2022 to 31st January 2023.
Material & Methods: Total 60 clinically diagnosed patients of symptomatic oral lichen planus were included in study, 60 patients were equally divided into two groups as Group A and group B.
Thirty patients of OLP group A were treated with Tracolimus 0.
1% four times per day for four weeks and patients of group B were treated with Triamcinolone Acetonide 0.
1% ointment.
Results: Total 60 symptomatic OLP patients were categorized into to equal groups A and B group.
OLP was commonly found in female as compare to male, VAS score and clinical score was calculated before and after the treatment, the mean VAS score of group A was 9.
2 (SD±2.
07) and group B was 8.
9 (SD±2.
07) before the treatment.
While VAS score of group A 1.
9 (SD±1.
18) which was treated with tacrolimus (0.
1%) and group B score was 2.
3 (SD±1.
49) which was treated with triamcinolone (0.
1%) after the treatment.
The mean clinical score of group A was 4.
2 (SD±1.
14) and 4.
6 (SD±1.
28) in group B before treatment.
Mean clinical score was 1.
8 (SD±0.
87) in group A and 2.
4 (SD±0.
9) in group-B after treatment.
Conclusion: Study reported Tacrolimus 0.
1% is more effective then triamcinolone 0.
1% for the treatment of symptomatic OLP however there was no reoccurrence found.
Related Results
Salivary Diagnosis: Detection of Several Intracellular Enzymes in Patients with Oral Lichen Planus
Salivary Diagnosis: Detection of Several Intracellular Enzymes in Patients with Oral Lichen Planus
Introduction: Oral lichen planus is a chronic inflammatory disease, presenting malignant potential. An association between chronic inflammation and initiation and progression of c...
Homocysteine and other cardiovascular risk factors in patients with lichen planus
Homocysteine and other cardiovascular risk factors in patients with lichen planus
AbstractBackgroundChronic inflammation was found to play an important role in the development of cardiovascular risk factors. Homocysteine (Hcy) and fibrinogen have been identified...
Ranolazine-Tacrolimus Interaction
Ranolazine-Tacrolimus Interaction
Objective: To report the case of a kidney allograft recipient on a stable regimen of tacrolimus who exhibited increased tacrolimus concentrations within 24 hours of initiating rano...
Comparison of Supratarsal Injection of Triamcinolone Acetonide and Topical Tacrolimus in the Treatment of Refractory Vernal Keratoconjunctivitis
Comparison of Supratarsal Injection of Triamcinolone Acetonide and Topical Tacrolimus in the Treatment of Refractory Vernal Keratoconjunctivitis
Vernal keratoconjunctivitis (VKC) is a chronic allergic ocular condition commonly affecting young individuals in tropical and subtropical regions. This study aimed to compare the e...
Serum angiopoietin‐2 level as a novel potential biomarker in oral lichen planus
Serum angiopoietin‐2 level as a novel potential biomarker in oral lichen planus
AbstractBackgroundLichen planus is a common chronic cutaneous inflammatory disease. Recent advances evidenced that angiogenesis is tightly connected to it. More recently, the endot...
Comparison of Efficacy of Oral Methotrexate and Acitretin for Generalized Lichen Planus
Comparison of Efficacy of Oral Methotrexate and Acitretin for Generalized Lichen Planus
Background: Generalized lichen planus is a chronic inflammatory dermatosis that often requires systemic therapy when widespread or resistant to topical treatment. Methotrexate and ...
Lichenoid vulvar dermatoses: clinical presentation, morphology, and dermatoscopic signs
Lichenoid vulvar dermatoses: clinical presentation, morphology, and dermatoscopic signs
Lichenoid vulvar dermatoses are a heterogeneous group of diseases characterized by a number of overlapping signs and/or morphological features. Clinical similarity is accounted for...
Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells
Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells
Background
Topical tacrolimus has been used for vitiligo as a common treatment option for more than ten years while the underlying mechanism is still uncertain. The aim...

